KTX-955

• Description :

  KTX-955 is an antumor and effective IRAK4 degrader, with DC50 values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively[1]. KTX-955 is composed of CRBN ligand (blue part) Pomalidomide (HY-10984) and target protein ligand (red part) IRAK4-IN-20 (HY-150735) .

• UNSPSC :

  12352005

• Target :

  IRAK; PROTACs

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation; PROTAC

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ktx-955.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(N1C2C(NC(CC2)=O)=O)C3=CC=CC(N[C@H]4C[C@@H](C4)OC5CCN(CC5)C[C@H]6CC[C@H](N7C=C8C(C=C(C(NC(C9=CC=CC(C(F)(F)F)=N9)=O)=C8)C(C)(O)C)=N7)CC6)=C3C1=O

• Molecular Formula :

  C46H51F3N8O7

• Molecular Weight :

  884.94

• References & Citations :

  [1]Matthew Weiss. Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications. Northeastern Section, ACS (NESACS) .|[2]Nello Mainolfi, et al. Irak degraders and uses thereof. WO2020264499A1

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  IRAK4

• CAS Number :

  [2573302-50-6]